NGPOD has signed an agreement with Biotech Medical in Qatar to distribute the NGPOD nasogastric tube placement confirmation system in the kingdom.
The deal is NGPOD's first agreement in the region which is seeing enormous growth in health spending.
Qatar's government has invested heavily in developing its healthcare system. Consequently, the healthcare industry has witnessed unprecedented growth, and the sector is estimated to reach $12 billion by 2024, reflecting an increase of 360 per cent compared to 2010.
Speaking about the agreement Marcus Ineson, Chief Marketing Officer of NGPOD Global Ltd, highlighted the size of the opportunity for the company, "We have been looking for the right partner for some time in this increasingly important healthcare market. We are delighted to be partnering with Biotech Medical, who have great experience in the clinical areas where NGPOD offers enormous benefits over heritage methods of nasogastric tube confirmation'"
NGPOD is a patented device that, in a UK based clinical trial, has been shown to reduce the risks associated with established methods of nasogastric tube placement, which can lead to serious clinical incidents (Never Events) which cause injury and death to patients. NGPOD also reduces the need for time-consuming, costly x-rays and allows patients to receive nutrition, hydration and medicines without delay supporting their recovery.
NGPOD Ltd manufactures the NGPOD system in the UK and has so far, in 2021, created six new high-quality life science manufacturing jobs at their new facility in Runcorn. Further announcements of other international distribution partnerships are imminent.
For more information Contact Us
WHAT IS NGPOD?